Los Angeles Capital Management LLC Mirati Therapeutics, Inc. Transaction History

Los Angeles Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$132.01 - $190.29 $177,817 - $256,320	-1,347 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$132.13 - $177.45 $177,979 - $239,025	1,347 New	1,347 $238,000
Q2 2021 Aug 05, 2021	SELL	$144.0 - $179.73 $1.38 Million - $1.72 Million	-9,562 Closed	0 $0
Q1 2021 May 05, 2021	SELL	$158.92 - $221.61 $1.61 Million - $2.24 Million	-10,112 Reduced 51.4%	9,562 $1.64 Million
Q4 2020 Feb 04, 2021	SELL	$162.05 - $240.27 $51,693 - $76,646	-319 Reduced 1.6%	19,674 $4.32 Million
Q3 2020 Nov 02, 2020	SELL	$113.26 - $167.27 $685,676 - $1.01 Million	-6,054 Reduced 23.24%	19,993 $3.32 Million
Q2 2020 Aug 05, 2020	BUY	$72.01 - $120.39 $1.88 Million - $3.14 Million	26,047 New	26,047 $2.97 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.